One of the pathological features of CLN3 disease is the increase in ceramide levels noted in brains of CLN3 and CLN2 disease patients, previously referred to as juvenile and late-infantile NCL, respectively [25]. This evidence concerns the gene TPP1 and neuronal ceroid lipofuscinosis.